October 26-27 2020 Boston, MA
At a time when there is crushing information overload around the COVID-19 pandemic, we wanted to share some articles and actions that the AI in Biopharma community are working on.
Read the latest work/updates from our Summit speakers, Advisory Board members and passionate community members
Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use
Mathai Mammen talks about leveraging specific technologies over many years: Our team continues to work tirelessly and creatively on a vaccine to prevent COVID-19. The work leverages some specific technologies that we have developed at Janssen over many years. And we aim to supply at least a billion doses. Our work is being supported by the US government agency BARDA (announcement below). Wish us luck. And make every effort to stay healthy in the meanwhile. Read full article here.
Naheed Kurji, Cyclica, talks about the need to keep investing in academic institutions and biotech companies via his announcement of the “Cylclica Stimulus Plan.” It’s disheartening to see academic institutions and biotech companies struggle to keep up with their drug discovery research due to COVID. If there’s ever a time to invest in #medicines, it’s now. So, today we are announcing the “Cyclica Stimulus Plan”. Through this plan, we offer our support with no up-front cost to institutions and biotech companies working on COVID-19 as well as those academic researchers working on identifying lifesaving treatment for other diseases whose labs have been impacted by COVID-19. If you find yourself in need of additional support is encouraged to apply via our website here. We’re here to help. Read the full article here.
In recent years, beyond the hype of artificial intelligence, the technology has gained criticism more than appreciation. Many experts fear its misuse and less collaborative behavior along with humans. However, as the coronavirus pandemic is spreading, AI is proving its worth above all. So far, the technology has served more good than bad amid the outbreak. AI is proving to the world that it can serve mankind with utmost sincerity. From assisting doctors to supplying emergency materials in the hospitals, AI has marked its value. Besides, technology is playing a great role in drug discovery and vaccine development against the COVID-19 virus. Read the full article here.
We’ve all heard a lot in the news about the unprecedented speed with which the FDA, NIH and private companies are moving to get therapies, antivirals, vaccines and testing kits for COVID-19. AI is playing a role in this to a large degree. Relatedly, AI is already playing a role in speeding up the drug discovery for rare diseases. As its latest trials move into next phase, founder and A HealthTech firm Healx using AI to speed up the creation of treatments for rare diseases has moved into the next phase of its most recent clinical trials. Read the full article here.
It’s not just about developing vaccines and treatments. AI plays a broader role in controlling a pandemic. From developing drug treatments to predicting the next hotspot, artificial intelligence may help researchers, healthcare workers, and everyday people offset the impact of the coronavirus. Read the full article here.
As we look to an uncertain future at the moment, I thought it would be uplifting right now to look at a possible road map to reopening. Former FDA Commissioner Scott Gottlieb wrote an excellent report describing criteria and scenarios for getting from here (Phase I) back to normal (Phase III). Read the full article here.
We will continue to post these and others on our AI Applications in Biopharma Summit website, along with some new podcasts being produced shortly; you can find them on our resources page. Subscribe for updates to receive all the latest insight.
Thanks for reading – we wish you good health in the weeks to come and please get in touch if you wish to contribute to the next blog.